Cancer Causes & Control

, Volume 21, Issue 10, pp 1657–1667

Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study

  • Mieke Van Hemelrijck
  • Hans Garmo
  • Elisa Binda
  • Adrian Hayday
  • Sophia N. Karagiannis
  • Niklas Hammar
  • Göran Walldius
  • Mats Lambe
  • Ingmar Jungner
  • Lars Holmberg
Original paper

DOI: 10.1007/s10552-010-9594-6

Cite this article as:
Van Hemelrijck, M., Garmo, H., Binda, E. et al. Cancer Causes Control (2010) 21: 1657. doi:10.1007/s10552-010-9594-6

Abstract

We quantified associations between IgE and cancer in a meta-analysis and cohort study. Pubmed and Embase were searched to extract information using predefined inclusion criteria. In the Apolipoprotein MOrtality RISk (AMORIS) database, 24,820 persons had IgE measurements. Multivariate Cox proportional hazard models were used to analyze associations between IgE and cancer. Twenty-seven studies were reviewed from which seven case–control studies were included for analysis. The pooled relative risk (random effects model) was 0.97 (95% CI 0.86–1.09). Cell types of tumor origin (mesenchymal tissue or cells of the nervous system, lymphatic or hematopoietic tissue, and epithelium) modified the effect. In the AMORIS cohort, 862 persons developed cancer. Hazard ratios comparing quartiles of IgE were similar to the findings in the meta-analysis (HR 0.87 (95% CI 0.72–1.06); 0.94 (0.78–1.14); 0.90 (0.74–1.10) for the 2nd, 3rd, and 4th quartile compared to the 1st quartile), but there was no pattern by tumor origin. Both studies showed a weak inverse association between IgE and cancer, but a pattern by cancer type was only seen in the meta-analysis. Our findings suggest the need for prospective studies studying IgE and cancer. Measurements of IgE should be combined with other information, e.g., bio-banked samples containing other key immunological discriminators.

Keywords

Cancer IgE Meta-analysis Sweden Atopy 

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Mieke Van Hemelrijck
    • 1
  • Hans Garmo
    • 1
    • 2
  • Elisa Binda
    • 3
  • Adrian Hayday
    • 3
    • 10
  • Sophia N. Karagiannis
    • 4
  • Niklas Hammar
    • 5
    • 6
  • Göran Walldius
    • 5
    • 7
  • Mats Lambe
    • 2
    • 8
  • Ingmar Jungner
    • 9
  • Lars Holmberg
    • 1
    • 2
  1. 1.Cancer Epidemiology GroupKing’s College LondonLondonUK
  2. 2.Regional Oncologic CentreUppsala UniversityUppsalaSweden
  3. 3.School of Medicine, Division of Immunology, Infection and Inflammatory Disease, Peter Gorer Department of ImmunobiologyKing’s College LondonLondonUK
  4. 4.School of Medicine, NIHR Biomedical Research Centre and Cutaneous Medicine and Immunotherapy Unit, St John’s Institute of Dermatology, Division of Genetics and Molecular MedicineKing’s College LondonLondonUK
  5. 5.Department of Epidemiology, Institute of Environmental MedicineKarolinska InstitutetStockholmSweden
  6. 6.AstraZeneca SverigeSödertäljeSweden
  7. 7.Department of MedicineKarolinska InstitutetStockholmSweden
  8. 8.Department of Medical Epidemiology and BiostatisticsKarolinska InstitutetStockholmSweden
  9. 9.Department of Medicine, Clinical Epidemiological Unit and CALAB ResearchKarolinska InstitutetStockholmSweden
  10. 10.Cancer ResearchLondon Research InstituteLondonUK